Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China

BMC Pulm Med. 2021 Feb 12;21(1):57. doi: 10.1186/s12890-021-01399-5.

Abstract

Background: Anti-synthetase syndrome (ASSD) is a chronic autoimmune condition characterized by antibodies directed against an aminoacycl transfer RNA synthetase (ARS) along with a group of clinical features including the classical clinical triad: inflammatory myopathy, arthritis, and interstitial lung disease (ILD). ASSD is highly heterogenous due to different organ involvement, and ILD is the main cause of mortality and function loss, which presents as different patterns when diagnosed. We designed this retrospective cohort to describe the clinical features and disease behaviour of ASSD associated ILD.

Methods: Data of 108 cases of ASSD associated ILD were retrospectively collected in Beijing Chaoyang Hospital from December 2017 to March 2019. Data were obtained from the Electronic Medical Record system. Patients were divided into 5 groups according to distinct aminoacyl tRNA synthetase (ARS) antibodies.

Results: Overall, 108 consecutive patients were recruited. 33 were JO-1 positive, 30 were PL-7 positive, 23 were EJ positive, 13 were PL-12 positive and 9 were OJ positive. The JO-1 (+) group had a significant higher rate of mechanic's hand (57.6%) than other 4 groups. Polymyositis/dermatomyositis (PM/DM) was diagnosed in 25 (23.1%) patients and no difference was observed among the 5 groups. The PL-7 (+) group had a higher frequency of UIP pattern (13.3%) than the other 4 groups but the difference was not significant, and the EJ (+) group had the most frequent OP pattern (78.2%), which was significantly higher than the PL-7 (+) (P < 0.001) and PL-12 (+) groups (P = 0.025). The median follow-up time was 10.7 months, during which no patients died. All received prednisone treatment, with or without immunosuppressants. At the 6-month follow-up, 96.3% of all patients (104/108) had a positive response to therapy, the JO-1 (+) and EJ (+) groups had a significantly higher improvement of forced vital capacity than the other 3 groups (P < 0.05), and the PL-7 group had the lowest FVC improvement (P < 0.05). The JO-1 (+) group and EJ (+) group had significantly higher anti-Ro-52 positive occurrence than the other 3 groups (P < 0.05).

Conclusion: Anti PL-7 antibody had the same frequency as anti-JO-1 in ASSD-ILD, in which the ILD pattern was different with distinct anti-ARS antibodies. Most ASSD-ILD had a positive response to steroid therapies, with or without immunosuppressants. The PL-7 (+) group had the highest occurrence of UIP pattern, and a significantly lower response to therapy.

Keywords: Anti-synthetase syndrome; Interstitial lung disease; Nonspecific interstitial pneumonia; Organizing pneumonia.

MeSH terms

  • Adult
  • Aged
  • Alanine-tRNA Ligase / immunology
  • Antibodies, Antinuclear / immunology
  • Autoantibodies / immunology*
  • China
  • Cohort Studies
  • Dermatomyositis / drug therapy
  • Dermatomyositis / immunology
  • Dermatomyositis / physiopathology*
  • Female
  • Glucocorticoids / therapeutic use
  • Glycine-tRNA Ligase / immunology
  • Humans
  • Idiopathic Pulmonary Fibrosis / drug therapy
  • Idiopathic Pulmonary Fibrosis / immunology
  • Idiopathic Pulmonary Fibrosis / physiopathology
  • Immunosuppressive Agents / therapeutic use
  • Isoleucine-tRNA Ligase / immunology
  • Lung Diseases, Interstitial / diagnostic imaging
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / immunology
  • Lung Diseases, Interstitial / physiopathology*
  • Male
  • Middle Aged
  • Myositis / drug therapy
  • Myositis / immunology
  • Myositis / physiopathology*
  • Prednisone / therapeutic use
  • Prognosis
  • Retrospective Studies
  • Threonine-tRNA Ligase / immunology
  • Treatment Outcome
  • Vital Capacity

Substances

  • Antibodies, Antinuclear
  • Autoantibodies
  • Glucocorticoids
  • Immunosuppressive Agents
  • Jo-1 antibody
  • SS-A antibodies
  • Glycine-tRNA Ligase
  • Threonine-tRNA Ligase
  • Isoleucine-tRNA Ligase
  • Alanine-tRNA Ligase
  • Prednisone

Supplementary concepts

  • Antisynthetase syndrome